In theory, DNA vaccination combines the most desirable attributes of standard vaccine approaches in order to achieve functional enhancement of antigen-specific immune cells. Attenuated vaccine antigens are poorly taken up by and processed through the MHC class I pathway and thus primarily induce humoral immune responses and only weakly activate cytotoxic T cells. In contrast, live attenuated vaccines generate both cellular and humoral immune responses, and, potentially, lifelong immunity. However, safety concerns make development of new vaccines based on live, replicating vectors costly. Possible reversion and possible pathogenesis of the immunogen in immunocompromised individuals limit development of some live attenuated vaccines. The development of safer and more efficacious vaccine strategies that elicit both strong cellular and strong humoral immunity without viral replication is currently under intense investigation. One possible solution is the development of more effective DNA vaccines.
What are the mechanisms of immunity following DNA vaccination?
The eff iciency of DNA vaccination depends on the interaction among genetic material, lymphocytes, and APCs. Following intramuscular injection, myocytes play the role of antigen factories. They primarily express MHC class I and under certain circumstances express MHC class II; however, they do not express the costimulatory molecules required for priming and activation of T cells and thus lack function as effective APCs (1). Alternatively, small numbers of bone marrow-derived DCs and other professional APCs that can be activated to express high levels of MHC, as well as costimulatory molecules, are present at the site of injection and become transfected with the injected DNA. Cross-priming may occur, in which CD8 + T cell responses are primed by exogenous class I-restricted peptides that are not expressed in, but rather are acquired by, local APCs (2, 3). Regardless of the underlying mechanism, it has become clear that in the context of DNA vaccination APCs are key inducers of immunity, as they are the pivotal mediators of immune responses between resident somatic cells and T cells in the lymph nodes. By trafficking antigen from the site of injection to the secondary lymphoid organs, APCs serve to efficiently present antigen to naive T cells.
Targeting DC maturation for improved DNA vaccine potency Based on the initial reports of immune enhancement by delivery of plasmids encoding GM-CSF (4) or IL-12 (5) in combination with specific antigen-encoded plasmids, other molecules have been studied for manipulating the potency of DNA vaccines in mice. Molecules under investigation target Th1-type T cell expansion; DC/APC activation, expansion, or maturation; costimulation; and immune cell trafficking by chemokines (4, (6) (7) (8) (9) (10) (11) (12) (13) . Recently, some vaccine strategies have produced exciting results in nonhuman primates (14, 15) .
The ability of DCs to drive antigenspecific immunity is dependent on their degree of maturation. As shown in Table  1 , a variety of molecules delivered as DNA vaccines can improve APC activation, expansion, or maturation following antigen uptake and processing in vivo. These include bacterially derived antigens, TNFsuperfamily receptors, growth factors, inf lammatory cytokines/chemokines, ligation of select cell surface receptors (CD40), and viral products. During their conversion from immature to mature cells, DCs undergo a number of phenotypic and functional changes, including increased MHC complex expression on their surface; increased surface expression of costimulatory molecules; morphological changes, including an increase in surface area, which allows DCs to interact with a greater number of T cells; secretion of chemokines and cytokines for attraction and expansion of T cells; protease production to convert molecules important in immune expansion to their active forms; and surface expression of adhesion molecules and chemokine receptors, allowing for increased interaction with other immune cells (Table 1) . Through the use of combination immunomodulatory adjuvants that code for maturation, activation, or recruitment factors, it should be possible to further manipulate APCs in vivo to enhance DNA vaccine potency.
In this issue of the JCI, Sumida et al. (16) explore a combination of DC-specific chemotactic and growth factors, macrophage inflammatory protein-1α (MIP-1α) and fms-like tyrosine kinase 3 ligand (Flt3L), as part of a DNA vaccine cocktail. Previous DNA vaccine studies have shown that MIP-1α, which binds to CC chemokine receptor 5 (CCR5) on immature DCs, is able to recruit DCs to the site of inoculation in mice, resulting in enhanced cellular immune responses and increased antibody titers (17) . In other studies, the use of maturation factors or DC growth factors such as Flt3L immunoadjuvants has been shown to expand DC numbers in both mice and humans (7, 18) . However, the combination of MIP-1α and Flt3L tested by Sumida et al. (16) extends those early studies by demonstrating DC recruitment to the site of injection and migration of loaded APCs to the regional lymph nodes (16) . Immunohistochemistry of injected muscle tissue shows that inoculation with plasmids encoding MIP-1α and Flt3L with HIV-1 envelope (env) DNA vaccine resulted in recruitment of DCs that express CD11b and the activation markers CD83 and S100, as well as the maturation markers MHC class II and CD80. In this model, DCs that traffic to the inoculation site in response to MIP-1α expression and contact Flt3L expressed on the muscle cells expand and mature in response to the growth factor Flt3L (Figure 1) . Upregulation of CCR7 and loss of CCR5 on the mature DCs will cause them to traffic to the draining lymph node, where immune priming can occur in the germinal centers (Figure 1 ).
In the current study (16) , vaccine-elicited immune responses were not detectably augmented by plasmid-encoded Flt3L or plasmid-encoded MIP-1α alone. In contrast, tetramer responses and IFN-γ responses were enhanced in mice that received the DNA vaccine along with both adjuvant plasmids. This finding is in contrast to earlier studies in which vaccination with MIP-1α expanded both humoral and cellular immune responses (17) and vaccination with Flt3L also exhibited enhancement of immunogenicity (18) . These differences may reflect the properties of different plasmid-based vectors, properties unique to the antigens involved, different forms of the adjuvants, or other, unknown biases.
Furthermore, improved protection against challenge with recombinant HIV env and vaccinia virus in mice was achieved following vaccination with plasmidencoded MIP-1α, Flt3L, and HIV-1 env DNA vaccine (16) . Prior studies have also shown enhanced immunogenicity and protection against lethal challenge with herpes simplex virus-2 in mouse model systems using chemokines that bind CCR5 as adjuvants. For example, RANTES coimmunization significantly enhanced CD8 + and CD4 + T cell responses and resulted in enhanced survival in a lethal mucosal herpes simplex virus-2 challenge model (19) . However, in the same system, immunization with MIP-1α alone was not effective, which suggests that not all CCR5 ligands are similar and that Flt3L, as reported here (16), complements MIP-1α activity.
Overall, these studies support a model where the number of DCs present at the site of inoculation during antigen expression is a possible rate-limiting factor for DNA vaccine effectiveness. In this context, coimmunization with a plasmid chemokine for attracting DCs to the site of injection appears important. For example, in other DNA vaccine studies, the use of apoptotic molecules as plasmid adjuvants results in the death of antigen-bearing cells, leading to an increase in antigen acquisition by APCs, including DCs (20, 21) .
Important issues that should be investigated include elucidation of how the antigenic plasmid is trafficked to APCs following immunization, the efficacy of different adjuvant combinations, the most relevant timing of adjuvant delivery, and validation using other antigenic plasmids in additional model systems. The question remains of exactly how and in what context DCs that migrate to the site of injection acquire plasma-delivered antigen. For future development of this strategy, validation needs to be carried out in primate models. Many vaccine studies have shown that mice and primates may not respond similarly to the same adjuvants. For example, GM-CSF was shown to be a superior adjuvant for DNA vaccines in mice but was a poor DNA adju- 
